Request Demo
Last update 23 Oct 2025
Opucolimab
Last update 23 Oct 2025
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms Opucolimab, 重组抗PD-L1全人单克隆抗体 (上海复宏汉霖生物), HLX-20 |
Target |
Action inhibitors |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 432307905L
Source: *****
Sequence Code 432307911H
Source: *****
Related
2
Clinical Trials associated with OpucolimabNCT03588650
A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting Programmed Death Ligand 1 (PD-L1) Protein in Patients With Advanced Solid Tumors
ACTRN12618000977279
A Phase 1 Study on the safety and maximum tolerated dose of HLX20, a Human Monoclonal Antibody Targeting Programmed Death Ligand 1 (PD-L1) Protein, in Patients with Advanced Solid Tumors
100 Clinical Results associated with Opucolimab
Login to view more data
100 Translational Medicine associated with Opucolimab
Login to view more data
100 Patents (Medical) associated with Opucolimab
Login to view more data
100 Deals associated with Opucolimab
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Solid tumor | Phase 2 | China | 30 Jan 2023 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | Australia | 07 Aug 2018 | |
| Colorectal Cancer | IND Approval | China | 02 Sep 2024 | |
| Esophageal Carcinoma | IND Approval | China | 02 Sep 2024 | |
| Hepatocellular Carcinoma | IND Approval | China | 02 Sep 2024 | |
| Melanoma | IND Approval | China | 02 Sep 2024 | |
| Microsatellite Instability-high Solid Tumors | IND Approval | China | 02 Sep 2024 | |
| Non-Small Cell Lung Cancer | IND Approval | China | 02 Sep 2024 | |
| Squamous Cell Carcinoma of Head and Neck | IND Approval | China | 02 Sep 2024 | |
| Triple Negative Breast Cancer | IND Approval | China | 02 Sep 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free